Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997

被引:127
作者
Cacoub, P
Geffray, L
Rosenthal, E
Perronne, C
Veyssier, P
Raguin, G
机构
[1] Hop La Pitie Salpetriere, Dept Internal Med, F-75651 Paris 13, France
[2] Hop Robert Bisson, Lisieux, France
[3] Hop Archet, Nice, France
[4] Hop Raymond Poincare, Garches, France
[5] Hop Compiegne, Compiegne, France
[6] Hop Croix St Simon, Paris, France
关键词
D O I
10.1086/319747
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Several studies have suggested that the progression of hepatitis C virus (HCV) infection is more severe in patients infected by the human immunodeficiency virus (HIV). Two national retrospective multicenter cohort surveys were performed in France that included 17,487 HIV-infected patients during 1995 and 26,497 during 1997. The following data was evaluated: total number of deaths; number of deaths linked to AIDS, cirrhosis, or hepatocellular carcinoma (HCC); and number of deaths related to other (non-HCV-linked) causes. In 1995, the causes of death were as follows: AIDS, 1307 (7.47%); cirrhosis or HCC, 21 (0.12%); and other (non-HCV-linked) causes, 99 (0.56%). In 1997, the causes of deaths were as follows: AIDS, 459 (1.73%); cirrhosis or HCC 36 (0.13%); and other (non-HCV-linked) causes, 48 (0.18%). Comparative results between the 1995 and 1997 surveys showed a dramatic decrease in AIDS-related mortality rates (7.47% vs. 1.73%; P < .001) but not in HCV-related mortality rates (0.06% vs. 0.07%; P = .79). In France, despite the high prevalence of HCV infection in HIV-positive patients, the mortality rate in 1995 and 1997 caused by HCV-related cirrhosis or HCC was low.
引用
收藏
页码:1207 / 1214
页数:8
相关论文
共 31 条
[1]
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].
Benhamou, Y ;
Bochet, M ;
Di Martino, V ;
Charlotte, F ;
Azria, F ;
Coutellier, A ;
Vidaud, M ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (04) :1054-1058
[2]
Buti M, 1996, J MED VIROL, V49, P66, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt
[3]
66::AID-JMV11&gt
[4]
3.0.CO
[5]
2-0
[6]
Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C [J].
Darby, SC ;
Ewart, DW ;
Giangrande, PLF ;
Spooner, RJD ;
Rizza, CR ;
Dusheiko, GM ;
Lee, CA ;
Ludlam, CA ;
Preston, FE .
LANCET, 1997, 350 (9089) :1425-1431
[7]
DEGOS F, 1994, FEMS MICROBIOL REV, V14, P267, DOI 10.1111/j.1574-6976.1994.tb00098.x
[8]
Denis F, 1997, PATHOL BIOL, V45, P701
[9]
EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602
[10]
PREVALENCE OF HEPATITIS-C IN A CHEMICALLY DEPENDENT POPULATION [J].
FINGERHOOD, MI ;
JASINSKI, DR ;
SULLIVAN, JT .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (17) :2025-2030